AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials

Rhea-AI Summary

Applied Genetic Technologies Corporation (Nasdaq: AGTC) is set to release 12-month data from its Phase 1/2 clinical trials on Achromatopsia (ACHM) on June 24, 2021. This data will cover adult and low-dose pediatric patients, specifically addressing the CNGB3 and CNGA3 gene therapies. Management will host a conference call at 8:00 AM ET to discuss the findings. AGTC focuses on gene therapies for rare retinal diseases and aims to improve vision in patients with inherited retinal conditions. The trial results could significantly influence AGTC’s market position.

Positive

• Upcoming release of 12-month clinical trial data on Achromatopsia could boost investor confidence.
• Focus on rare retinal diseases positions AGTC in a niche, potentially lucrative market.

Negative

• No current data available for evaluation, leaving investors uncertain about trial outcomes.
• -

GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it plans to release 12-month data for adult patients and low dose pediatric patients in its Phase 1/2 clinical Achromatopsia (ACHM) trials on Thursday, June 24, 2021. AGTC management will host a conference call and webcast with accompanying slides beginning at 8:00 AM Eastern Time on the same date to review the ACHM CNGB3 and CNGA3 data and provide an update on the trials.

The live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations. To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). The archived webcast and slide presentation will be available in the Events and Presentations section of the Company's website.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.

IR/PR CONTACTS: 
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: 212-867-1768 or 646-871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contact:
Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: 617-413-2754
spotter@agtc.com 

FAQ

What is the significance of AGTC's 12-month data release on June 24, 2021?

The 12-month data release is crucial as it will reveal the efficacy and safety results from the Phase 1/2 trials for Achromatopsia, directly influencing investor sentiment.

What trials are AGTC conducting related to Achromatopsia?

AGTC is conducting Phase 1/2 clinical trials targeting the CNGB3 and CNGA3 gene therapies for Achromatopsia, a rare retinal disease.

How will the upcoming AGTC conference call impact shareholders?

The conference call will provide a detailed review of the trial data, which can significantly affect AGTC's stock performance based on the results presented.

What types of diseases is AGTC focusing on in their gene therapy development?

AGTC is focused on developing gene therapies for rare ophthalmic, otologic, and CNS diseases, particularly inherited retinal diseases.